<DOC>
	<DOCNO>NCT03086005</DOCNO>
	<brief_summary>This study perform investigate effect metformin control ovarian stimulation ( COS ) , vitro fertilization ( IVF ) outcomes , pregnancy outcome , comparison serum follicular fluid cytokine hormone patient polycystic ovary syndrome ( PCOS ) undergo IVF use gonadotropin-releasing hormone ( GnRH ) antagonist protocol .</brief_summary>
	<brief_title>Study Assess Effect Metformin Supplementation IVF Outcome Patients With Polycystic Ovarian Syndrome .</brief_title>
	<detailed_description>Polycystic ovary syndrome common cause female infertility feature insulin resistance hyperinsulinemia participate reproductive well metabolic disturbance . In many study , metformin treatment reduces androgen level attenuate hyperinsulinemia woman PCOS . This favorable effect insulin androgens level , justifies use metformin reproductive disturbance PCOS woman . Metformin treatment show diminish ovarian androgen secretion , lower insulin level woman PCOS . In woman PCOS , metformin treatment may increase ovulation , improve menstrual cyclicity , reduce seum androgen level . Metformin direct effect ovary also reduce level insulin act upon ovary . It indicate metformin direct , insulin-independent action theca cell steroidogenesis , human ovarian theca-like tumor cell , metformin suppress androstenedione production . Metformin also exert direct effect granulosa cell subsequent reduction steroid production . Metformin show improve endothelium dependent vasodilation insulin resistant patient potentially protect atherogenesis cardiovascular disease . Considering gonadotropin ovulation induction IVF woman PCOS , metformin coadministration improve pregnancy outcome reduces risk ovarian hyperstimulation syndrome . Metformin therapy throughout pregnancy reduce risk early miscarriage incidence gestational diabetes . All patient pretreated 3 week monophasic oral contraceptive ( OC ) ( Yasmin ; Bayer Schering Pharma , Berlin , Germany ) COS. Five day OC discontinuation , COS IVF/ICSI commence . GnRH antagonist protocol use COS subject . Patients randomly allocate metformin control group , use seal envelope .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>PCOS diagnostic criterion 2003 American Society Reproductive Medicine ( ARSM ) /European Society Human Reproduction Embryology ( ESHRE ) consensus meeting guideline include two three 1 . Oligo anovulation 2 . Clinical or/and biochemical hyperandrogenism 3 . Polycystic ovary ultrasound , exclusion etiology ( ≥ 12 follicle ( 29 mm diameter ) ovary ovarian volume ( 0.5 x length x width x thickness ) ≥ 10cm3 ) Anatomical normal uterus Normal level thyroid hormone Severe endometriosis ( stageIII , IV ) Endometrial thickness le 7mm late follicular phase Severe male infertility factor , nonobstructive azoospermia History ectopic pregnancy abortion last 3 month Unexplained abnormal uterine bleeding Congenital adrenal hyperplasia Androgen secrete tumor Cushing syndrome Concurrent administration metformin , ovulation induction drug , oral contraceptive within previous 3 month Chronic disease ( liver , kidney , severe heart failure , DM ) Any pathology genital tract History alcohol abuse Refuse study participate consent</criteria>
	<gender>Female</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Metformin</keyword>
</DOC>